ArticleFuture science OA2025
Pinpointing an innovative autophagic signature as a prognostic and diagnostic biomarkers in colorectal carcinoma.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutophagy is balanced machinery that supports anti-malignant mechanism via the removal of dysfunctional proteins, ROS and DNA abnormalities. Appropriate autophagic machinery is fundamental for mutant eradication and suitable genomic constancy thus it prevents the genetic faults aggregation which contributes to malignant conversion. This article focuses on the application of liposomal-formulated Nano-medicine as prospective therapy for colon carcinoma and the complemented autophagic deviation. RESEARCH DESIGN AND
methodsColon carcinoma was induced experimentally in rat model via 3-Methyl cholantherene (3-MCA) for 6 months proceeded with liposomal Isethione, Turmeric and Adriamycin treatment for 1 month and was further compared with their non-liposomal analogue. Concomitant supplementation with the aforementioned liposomal-formulated Nano-medicine influence on the gene expression of autophagy biomarkers including X-box binding protein 1 (XBP), C/EBP homologous protein (CHOP), activating transcription factor 4 (ATF-4) and Beclin in addition to, angiogenic biomarker (NOX) and oxidative stress biomarker (Butryl cholinesterase
resultsLiposomal-formulated Nano-medicine modulated the deviated autophagy biomarkers and oxidative and nitosative stress biomarkers in addition to, modulating histomorphological changes induced post 3-MCA colorectal cancer induction. Autophagy was involved in all steps of colon cancer progression and apoptosis.
conclusionliposomal-formulated Nano-medicine might be a prospective candidate for colorectal carcinoma treatment via modulating autophagy XBP/ATF4/Beclin/CHOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.